Literature DB >> 2804206

Temporal and topographic changes in DNA synthesis after induced follicular atresia.

G S Greenwald1.   

Abstract

Hamsters were hypophysectomized on the morning of estrus (Day 1) and injected immediately with 30 IU pregnant mare's serum (PMS). This was followed on Day 4 by the injection of an antiserum to PMS (PMS-AS) that initiated follicular atresia (Time zero). From 0 to 72 h after PMS-AS, the animals were injected with [3H]thymidine and killed 4 h later. One ovary was saved for autoradiography and histology; from the other ovary, 5-10 large antral follicles were dissected and pooled, and incorporation into DNA was determined by scintillation counting. DNA synthesis dropped sharply between 12 and 18 h, coinciding with a fall in labeling index of the cumulus oophorus and thecal endothelial cells and a sharp fall in thecal vascularity. In contrast, for the mural granulosa cells bordering on the antral cavity, labeling index dropped sharply between 8 and 12 h when thecal vascularity was still high. The earliest sign of atresia was evident by 4 h in cumulus cells when, paradoxically, DNA synthesis was still high. It took 3 days for atresia of the antral follicles to progress to advanced stages, as evidenced by pseudo-pronuclei in the free floating ovum, further erosion of the mural granulosa, and minimal DNA/follicle. However, the theca still retained its histological integrity and contained no pyknotic cells. Although by 48 h the granulosal compartment was in disarray (DNA/follicle significantly different from earlier values), the egg was still viable, as judged by maximal fluorescence after the addition of fluoroscein diacetate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2804206     DOI: 10.1095/biolreprod41.1.175

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  8 in total

Review 1.  Angiogenesis in the corpus luteum.

Authors:  L P Reynolds; A T Grazul-Bilska; D A Redmer
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

Review 2.  Angiogenesis in the female reproductive organs: pathological implications.

Authors:  Lawrence P Reynolds; Anna T Grazul-Bilska; Dale A Redmer
Journal:  Int J Exp Pathol       Date:  2002-08       Impact factor: 1.925

3.  VEGF, bFGF and swine granulosa cells: proliferation, steroidogenesis and NO production.

Authors:  F Grasselli; M Tirelli; V Cavalli; S Bussolati; C Tamanini
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

4.  Developmental Programming: Does Prenatal Steroid Excess Disrupt the Ovarian VEGF System in Sheep?

Authors:  Hugo Héctor Ortega; Almudena Veiga-Lopez; Shilpa Sreedharan; Melisa María del Luján Velázquez; Natalia Raquel Salvetti; Vasantha Padmanabhan
Journal:  Biol Reprod       Date:  2015-07-15       Impact factor: 4.285

5.  The genomic response of human granulosa cells (KGN) to melatonin and specific agonists/antagonists to the melatonin receptors.

Authors:  Asma Arjoune; Marc-André Sirard
Journal:  Sci Rep       Date:  2022-10-20       Impact factor: 4.996

Review 6.  The balance of proangiogenic and antiangiogenic VEGFA isoforms regulate follicle development.

Authors:  Renee M McFee; Timothy G Rozell; Andrea S Cupp
Journal:  Cell Tissue Res       Date:  2012-02-10       Impact factor: 5.249

7.  Effect of antiprogesterone RU486 on VEGF expression and blood vessel remodeling on ovarian follicles before ovulation.

Authors:  Annunziata Mauro; Alessandra Martelli; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Oriana Di Giacinto; Mauro Mattioli; Barbara Barboni
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

8.  Effects of P4 Antagonist RU486 on VEGF and Its Receptors' Signaling during the In Vivo Transition from the Preovulatory to Periovulatory Phase of Ovarian Follicles.

Authors:  Annunziata Mauro; Paolo Berardinelli; Valentina Russo; Nicola Bernabò; Alessandra Martelli; Delia Nardinocchi; Oriana Di Giacinto; Maura Turriani; Barbara Barboni
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.